Wegovy maker Novo Nordisk to cut costs as weight-loss competition heats up

Novo Nordisk is facing significant pressure on its blockbuster weight-loss drug Wegovy due to persistent competition from U.S. compounding pharmacies and rival Eli Lilly, leading to a $95 billion market value loss and a 30% share plunge last week. The company now expects continued high usage of compounded GLP-1s, not assuming a reduction this year despite earlier FDA actions, and has reiterated its lowered 2025 sales growth forecast while appointing a new CEO. Although Q2 sales and EBIT rose, Novo anticipates deeper erosion in Wegovy's key U.S. market in H2 due to increased discounts and rebates, underscoring ongoing challenges in the booming weight-loss drug market.

Analysis

Novo Nordisk is confronting a significant erosion of investor confidence and a material shift in its operational outlook, driven by persistent competition for its blockbuster obesity drug, Wegovy. The company's recent profit warning, which erased $95 billion in market value and triggered a 30% stock plunge, was rooted in the acknowledgment that competition from U.S. compounding pharmacies will not diminish this year as previously anticipated. This is a critical reversal, as over one million U.S. patients continue to use these copycat GLP-1 drugs, directly impacting Novo's market share. While second-quarter results showed a 67% year-over-year rise in Wegovy sales and a 29% increase in EBIT, total revenue of 76.86 billion Danish crowns missed forecasts, and the company has reiterated its lowered 2025 sales growth guidance of 8%-14%, down from 13%-21%. Further pressure is expected in the second half of the year, with the company forecasting deeper margin erosion in the key U.S. market due to higher rebates and a less favorable sales channel mix. The appointment of a new CEO, combined with a stated focus on "savings and efficiencies," signals a strategic pivot from unbridled growth to a more defensive posture in response to these mounting pressures from compounded drugs and rival Eli Lilly.

Key Decisions for Investors

• Investors should treat the unabated competition from U.S. compounded drugs as a primary near-term risk, as Novo Nordisk's revised guidance is now predicated on this headwind continuing throughout the year.
• It is prudent to re-evaluate valuation models to reflect the significantly lower 2025 sales growth forecast of 8-14% and the explicit warning of U.S. margin compression in the second half of the year.
• Closely monitor Wegovy's U.S. market share and pricing data relative to both compounded alternatives and rival Eli Lilly, as this competitive dynamic is the central threat to the company's growth narrative.
• The new CEO's strategy for achieving 'savings and efficiencies' warrants scrutiny, as this defensive cost-management focus may not be sufficient to offset the significant top-line pressures now facing the company.